Reach Us +1-218-451-2974


Disinhibition Associated with Long-term Use of Donepezil | OMICS International | Abstract
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Disinhibition Associated with Long-term Use of Donepezil

Tatsuru Kitamura* and Shoryoku Hino

Department of Neuropsychiatry, Ishikawa Prefectural Takamatsu Hospital, Ya-36, Uchi-Takamatsu, Kahoku-City, Ishikawa, Japan

*Corresponding Author:
Tatsuru Kitamura
Department of Neuropsychiatry, Ishikawa Prefectural Takamatsu Hospital
Ya-36, Uchi-Takamatsu, Kahoku-City, Ishikawa, Japan, 929-1293
Tel: +81-76-281-1125
E-mail: [email protected]

Received date: March 24, 2016; Accepted date: May 02, 2016; Published date: May 09, 2016

Citation: Kitamura T, Hino S (2016) Disinhibition Associated with Long-term Use of Donepezil. J Alzheimers Dis Parkinsonism 6:234. doi:10.4172/2161-0460.1000234

Copyright: © 2016 Kitamura T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Neuropsychiatric adverse events related to the long-term use of donepezil are not well known. Herein we report on two very elderly patients with Alzheimer’s disease in whom Disinhibition occurred after at least 5 years of oral donepezil.

Neither of the two patients (one an 88-year-old woman and the other a 98-year-old woman) had a history of preexisting psychiatric disorder, and no adverse events had been noted after starting donepezil prior to the development of Disinhibition. After discontinuation of donepezil, Disinhibition resolved within 1-2 months, during which time there were no physical, environmental, or other prescription changes.

A causal relationship between donepezil and Disinhibition was considered to be present. There have been no reports of Disinhibition associated with donepezil use in patients with Alzheimer’s disease. As we enter into a superaging society, further studies are needed to determine how long donepezil should be administered.